The Organizing Committee hopes to see you at Eurocarb18 in Moscow. We have several great opportunities for you to support this conference and showcase your professional services or innovative materials and equipment through sponsoring and exhibiting.





CordenPharma is a full-service CDMO partner in manufacturing of APIs and Drug Products organized under six Technology Platforms - Peptides / Lipids / Carbohydrates, Injectables, Highly Potent, Small Molecules, Antibiotics, Oncology - and supported by multiple cGMP manufacturing facilities across Europe and the USA. CordenPharma Switzerland is a well-recognized expert in peptides, lipids, carbohydrates and conjugates. The company provides a full range of Carbohydrate Synthesis & Production services from early-stage discovery through to commercial cGMP manufacturing:

  • Custom Carbohydrate Synthesis ( Any Scale / Stage)
  • Carbohydrate Conjugates (Glycopeptides, Glycolipids)
  • Multi-Step Process Engineering Expertise
  • Track Records in Regulatory Filing (e.g. IND, IMPD, NDA, ANDA)
  • Successful Inspection History from all Major Authorities (e.g FDA, EMEA)
Carbosynth is a specialist carbohydrate and nucleoside company.  We have diverse and broad experience in these chemistries that range from small laboratory scale multi-step synthesis to large scale multi-tonnage manufacture.

Carbosynth has an extensive catalogue of carbohydrates and nucleosides for R&D scientist in the international life science communities.  There are over 5,000 sugars and more than 1,500 nucleosides in the catalogue many of which are available promptly from stock from one of our distribution hubs in Compton, UK, San Diego, USA and Suzhou, China    We have a strong team of carbohydrate and nucleoside chemists and analysts who support the catalogue and strive to provide products on time and in specification every time.

We synthesise catalogue products in our laboratories, but also undertake custom synthesis.  Our chemistries range from carbohydrate synthesis to extraction, separation and purification of natural polysaccharides.    We are pleased to discuss your specific custom synthesis requirement and operate under CDA.

 Springer The world is full of publishers. Some move forward, some go backward, and some even seem to go nowhere at all. But at Springer we move in our own unique way.

With more than 200 Nobel Prize winners among the authors of our books and journal articles, it is safe to say that Springer has earned its place among the world’s foremost STM publishers. As an e-first company our editors  discover the best authors and help to disseminate their research, while our developers deliver the next big thing in scholarly communications. Our dedicated teams crisscross the globe to get journal articles, books, protocols and other products into the hands of the researchers, librarians and practitioners who need them most.

Much has happened since Julius Springer set up shop in Berlin in 1842. Whether you are using or producing research, a society looking for a partner, simply want to learn more or all of the above, look no further than Springer for your choice in publishing partners.

The Russian Foundation for Basic Research takes significant place in system of the organization of Russian science. Now the RFBR is the not only existing structure, but also the new system of the relations covering all aspects of scientific community life. The RFBR supports the most active scientific and technical potential of the country, provides scientists of Russia with financial support, realizes competitive funding mechanisms for scientific researches on the basis of expert estimates.

Mizutani Foundation logo

Mizutani Foundation for Glycoscience is a nonprofit organization established on October 1, 1992. The aim of the Foundation is to promote worldwide progress of glycoscience, especially that of glycoconjugates.

The aim of Mizutani Foundation is to contribute to the welfare of mankind through promotion of basic studies on glycoconjugates mainly by distributing research grants to qualified scientists regardless of their nationalities or ethnic origins. The Foundation may also support international conferences on glycoscience to facilitate exchanges between Japanese and foreign glycoscientists and carry out other activities that are vital for the progress of glycoconjugate-related sciences.


For over 135 years, Elsevier has been helping professionals advance knowledge by expanding the body of information, and enabling it to yield positive, measurable results.

Elsevier is an information solutions company with roots in publishing scientific, medical, and technical literature. We continue to produce intellectual content—largely in the form of digitized books, journals, and proprietary databases—via web-based and offline channels.  In addition through our platforms, we provide integrated technology and analytics that enable clients and end-users to do ‘more with’ information: to interact with it, manipulate it, share it, and extract intelligence with greater flexibility, efficiency, and creativity.

re.jsx GSK is a world’s leading vaccine company, with a comprehensive portfolio of 40 vaccines for infants, adolescents and adults and 17 more in development. We have more than 16,000 people working worldwide to deliver over 2.5 million vaccines safely, every day, to people in 90% of the world’s countries.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

GSK is a world’s leading vaccine company, involved in vaccine research, development and production. We have 17 candidate vaccines in development and our broad portfolio of 40 vaccines prevent illnesses such as hepatitis, whooping cough, pneumonia, measles, typhoid, influenza and meningitis. Globally, we have more than 16,000 people working to deliver vaccines safely, every day, to people in 90% of the world’s countries. In 2014 we distributed around 800 million doses of vaccine, 80% of them to least developed, low and middle income countries.

Безымянный-4 BioChemMack was founded in 1989 as one of the first Moscow University technology start-ups. The company founders, all Moscow University graduates, built the company on the vision of taking innovative technologies and making them broadly available to clinical diagnostics and research laboratories. The new venture secured its seed round of funding from Bio-Rad Laboratories, IMACK and Moscow University.

The vision of company founders with its absolute focus on customer success continues to guide BioChemMack today.  It shaped the company into an organization that consistently earns high marks from its customers, partners, employees and shareholders.

The company track record of quality, integrity and commitment to innovation follows the best traditions of Moscow University – the top school from which BioChemMack continues to draw talent and ideas.

With a portfolio of more than 25,000 of its own and partner company products, BioChemMack serves more than 5,000 diagnostics and life sciences customers in Russia and neighboring countries. The company follows best international business practices. Its quality system has been certified to ISO 9001 standard.